Home

helps physicians and healthcare professionals

Erectile Dysfunction

helps physicians and healthcare professionals

Doctor123.org

helps physicians and healthcare professionals

Giardiasis, Emergency Medicine


Basics


Description


  • Noninvasive diarrhea
  • Found worldwide:
    • 2-15% prevalence in developed nations
    • 20-40% prevalence in developing nations
  • 5% of all travelers' diarrhea
  • Most common intestinal parasite in US:
    • Highest incidence in early summer months through fall
    • Highest incidence in children aged 1-9 yr and adults aged 30-39 yr
    • In 2010, 19,888 cases reported in US (mostly from Northern States)
  • Fecal-oral transmission:
    • Humans are major reservoir
    • Zoonotic reservoir in both domestic and wild mammals
    • Reservoir in contaminated surface water
  • Populations at risk:
    • Travelers to endemic areas (developing countries, wilderness areas of US)
    • Children in day care centers and their close contacts
    • Institutionalized persons
    • Practitioners of anal sexual activity

Etiology


  • Giardia lamblia:
    • A protozoan flagellate
  • Also called Giardia intestinalis or Giardia duodenalis
  • Ingested Giardia attach to intestinal villi
  • Alters the intestinal brush-border enzymes, impairing digestion of lactose, and other saccharides
  • No toxin produced

Diagnosis


Signs and Symptoms


History
  • Onset 1-2 wk postexposure
  • Infection may be asymptomatic (most common).
  • Diarrhea of acute onset (90% of symptomatic patients):
    • Foul-smelling stools
    • Steatorrhea
    • Nonbloody
    • Self-limiting within 2-4 wk
    • More severe in immunocompromised patients and patients with underlying bowel disease
  • Flatulence and bloating (70-75%)
  • Abdominal cramping (70%)
  • Nausea (70%)
  • Vomiting (30%)
  • Malaise (86%)
  • Anorexia (66%)
  • Weight loss (60-70%)
  • Fever is rare (15%)
  • 30-50% of acute cases progress to chronic giardiasis (>4 wk):
    • Fat malabsorption
    • Severe macrocytic anemia secondary to folate deficiency
    • Secondary lactase deficiency (in 20-40% of patients)
  • Infection is more severe and harder to eradicate in immunosuppressed patients.

  • Acute infection:
    • Severe dehydration
  • Chronic infection:
    • Failure to thrive
    • Growth retardation and cognitive impairment owing to nutrient malabsorption

Physical Exam
  • Abdominal exam is benign.
  • Extraintestinal manifestations (10% of patients):
    • Polyarthritis
    • Urticaria
    • Aphthous ulcers
    • Maculopapular rash
    • Biliary tract disease

Essential Workup


  • History:
    • Possible sources of exposure
    • Membership in high-risk group
  • Physical exam:
    • If gross or occult blood on digital rectal exam, unlikely to be Giardia

Diagnosis Tests & Interpretation


Lab
  • Stool sample for microscopy (ova and parasites):
    • 50-70% sensitive if 1 sample
    • 85-90% sensitive if 3 samples taken at 2-day intervals (ideal)
    • 100% specific
    • Ability to detect other parasites as well
  • Stool ELISA or immunofluorescent antibody (IFA) assay for Giardia antigen:
    • 95% sensitive, 95-100% specific
    • Unlike microscopy, cannot rule out other parasites
  • Stool polymerase chain reaction (PCR):
    • 100% sensitive and 100% specific
  • Fecal leukocytes and stool culture unnecessary unless enteroinvasive organisms suspected (fever, bloody stool)
  • Serology for anti-Giardia antibodies not helpful in the ED setting
  • Electrolytes, BUN/creatinine, glucose:
    • If prolonged diarrhea or evidence of dehydration
  • CBC:
    • Macrocytic anemia in chronic giardiasis
    • Nondiagnostic in acute giardiasis

Imaging
Abdominal CT or ultrasound may show bowel wall thickening and flattened duodenal folds (nonspecific findings)  
Diagnostic Procedures/Surgery
  • Duodenal sampling:
    • Entero-Test (patient swallows a weighted string, which is later retrieved and examined for Giardia using microscopy)
  • Endoscopy:
    • Duodenal aspiration
    • Endoscopic duodenal biopsy

Differential Diagnosis


  • Viral gastroenteritis:
    • Norwalk virus
    • Rotavirus
    • Hepatitis A
  • Bacterial infections:
    • Staphylococcus
    • Escherichia coli
    • Shigella
    • Salmonella
    • Yersinia
    • Campylobacter
    • Clostridium difficile
    • Vibrio cholerae
  • Other protozoa:
    • Cryptosporidium
    • Microsporidia
    • Cyclospora
    • Isospora
    • Entamoeba
  • Inflammatory bowel disease
  • Irritable bowel syndrome
  • Lactase deficiency
  • Tropical sprue
  • Drugs and toxins:
    • Antibiotics
    • Calcium channel blockers
    • Magnesium antacids
    • Caffeine
    • Alcohol
    • Sorbitol
    • Laxative abuse
    • Quinidine
    • Colchicine
    • Mercury poisoning
  • Endocrine:
    • Addison disease
    • Thyroid disorders
  • Malignancy:
    • Colorectal carcinoma
    • Medullary carcinoma of the thyroid

Treatment


Initial Stabilization/Therapy


  • ABCs: Airway, breathing, circulation
  • IV 0.9% NS if signs of significant dehydration

  • For severe dehydration (>10%):
    • IV bolus with 0.9% NS at 20 mL/kg
    • Cardiac monitor
    • Blood glucose determination

Ed Treatment/Procedures


  • Oral fluids for mild dehydration
  • Correct any serum electrolyte imbalances.
  • Stool sample for microscopy
  • If stool sample is positive for Giardia: Treat as listed below under medication
  • If stool sample negative for Giardia:
    • Refer to gastroenterologist for further specialized testing.
    • Consider empiric course of metronidazole if high suspicion for Giardia.

Medication


First Line
  • Metronidazole or tinidazole are the treatment of choice:
    • 90% cure rate for each
  • Metronidazole: 250-500 mg (peds: 15 mg/kg/24h) PO q8h for 5-10 days
  • Tinidazole: 2 g (peds [>3 yr]: 50 mg/kg) PO once

Second Line
Albendazole (78-90% efficacy), quinacrine (90% efficacy), or nitazoxanide (75% efficacy) if 1st-line therapy fails  
  • Albendazole: 400 mg (peds: 10-15 mg/kg/24h) PO daily for 5-7 days
  • Furazolidone: 100 mg (peds: 6-8 mg/kg/24h) PO q6h for 7-10 days (not available in US)
  • Nitazoxanide: 500 mg (peds: 100 mg for ages 2-3 yr, 200 mg for ages 4-11 yr) PO BID for 3 days
  • Paromomycin: 500 mg (peds: 25-30 mg/kg/24h) PO q8h for 5-10 days
  • Quinacrine: 100 mg (peds: 6 mg/kg/24h) PO q8h for 5-7 days (limited availability)

  • Metronidazole is 1st-line therapy (80-95% efficacy)
  • Alternatives:
    • Furazolidone (80-85% efficacy)
    • Nitazoxanide (60-80% efficacy)
    • Paromomycin (55-90% efficacy)

  • Metronidazole contraindicated in 1st trimester
  • Albendazole, quinacrine, and tinidazole are contraindicated throughout pregnancy
  • Use nitazoxanide instead
  • If mild symptoms only, consider deferring treatment until late pregnancy or postpartum

Immunocompromised Considerations
  • Immunocompromised patients at risk for disease that is refractory to standard drug regimens:
    • Try drug of a different class/mechanism or metronidazole + quinacrine for at least 2 wk

  • Use furazolidone in older children only:
    • Causes hemolytic anemia in infants
    • Causes hemolytic anemia in persons with G6PD deficiency
  • Avoid quinacrine in G6PD deficiency (causes hemolytic anemia)
  • Avoid paromomycin in renal failure

Follow-Up


Disposition


Admission Criteria
  • Hypotension or tachycardia unresponsive to IV fluids
  • Severe electrolyte imbalance
  • Children with >10% dehydration
  • Signs of sepsis/toxicity (rare in isolated giardiasis)
  • Patients unable to maintain adequate oral hydration:
    • Extremes of age, cognitive impairment, significant comorbid illness

Discharge Criteria
  • Able to maintain adequate oral hydration
  • Dehydration responsive to IV fluids

Follow-Up Recommendations


  • Gastroenterology referral for diagnostic endoscopy if symptoms persist for >4 wk despite drug therapy
  • Acquired lactose intolerance may develop and last for weeks to months
  • Association with postinfectious fatigue syndrome

Pearls and Pitfalls


Diagnosis is the greatest challenge in this disease:  
  • Include giardiasis in the differential diagnosis of all patients with diarrhea:
    • Giardia occasionally reported in domestic water supply
    • Patients may not present with the classic history and risk factors to have giardiasis
    • 1 stool sample is frequently insufficient for diagnosis

Additional Reading


  • Escobedo  AA, Almirall  P, Alfonso  M, et al. Treatment of intestinal protozoan infections in children. Arch Dis Child.  2009;94:478-482.
  • Escobedo  AA, Alvarez  G, Gonz ¡lez  ME, et al. The treatment of giardiasis in children: Single-dose tinidazole compared with 3 days of nitazoxanide. Ann Trop Med Parasitol.  2008;102:199-207.
  • Escobedo  AA, Cimerman  S. Giardiasis: A pharmacotherapy review. Expert Opin Pharmacother.  2007;8:1885-1902.
  • Huang  DB, White  AC. An updated review on Cryptosporidium and Giardia. Gastroenterol Clin NorthAm.  2006;35:291-314.
  • Kiser  JD, Paulson  CP, Brown  C. Clinical inquiries. Whats the most effective treatment for giardiasis? J Fam Pract.  2008;57(4):270-272.
  • Naess  H, Nyland  M, Hausken  T, et al. Chronic fatigue syndrome after Giardia enteritis: Clinical characteristics, disability, and long-term sickness absence. BMC Gastroenterol.  2012;12:13.
  • Yoder  JS, Gargano  JW, Wallace  RM, et al. Giardiasissurveillance-United States, 2009-2010. MMWR Surveill Summ.  2012;61(5):13-23.

See Also (Topic, Algorithm, Electronic Media Element)


  • Amebiasis
  • Diarrhea, Adult

Codes


ICD9


007.1 Giardiasis  

ICD10


A07.1 Giardiasis [lambliasis]  

SNOMED


  • 58265007 Giardiasis (disorder)
Copyright © 2016 - 2017
Doctor123.org | Disclaimer